Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

Status:
Completed

Trial end date:
2021-06-22

Target enrollment:

Participant gender:

Efficacy and safety of LNP023 in IgAN patients

Phase 2

Novartis Pharmaceuticals